Market revenue in 2021 | USD 948.6 million |
Market revenue in 2030 | USD 3,180.3 million |
Growth rate | 14.4% (CAGR from 2021 to 2030) |
Largest segment | Targeted therapy |
Fastest growing segment | Targeted Therapy |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Targeted Therapy |
Key market players worldwide | Bayer AG, Bristol-Myers Squibb Co, Eisai Co Ltd, Merck KGaA, Exelixis Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer drug market will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 100% in 2021. Horizon Databook has segmented the North America liver cancer drug market based on targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America liver cancer drug market , including forecasts for subscribers. This continent databook contains high-level insights into North America liver cancer drug market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account